Enliven Therapeutics Inc.

ELVN | NASDAQ

Price Alert Chart Builder DCF Calculator

$48.87

-$0.58 (-1.17%)

At close: Sep 21, 2026, 4:00 PM ET

$48.30

-$0.57 (-1.17%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $3.53B

Enterprise Value $2.6B

Beta 0.25

Average Volume 1.21M

Shares Outstanding (Diluted) 66.17M

Shares Change YoY 27%

Institutional Ownership 99.35%

Exchange NASDAQ

ISIN US29337E1029

Price Performance

Price Change 1M -18.2%

Price Change 3M 0.6%

Price Change 6M 37.5%

Price Change YTD 214.5%

Price Change 1Y 145.3%

Price Change 3Y 271.1%

Price Change 5Y 190.9%

1M CAGR (ann.) -17.9%

1Y CAGR (ann.) 160.0%

5Y CAGR (ann.) 22.9%

All-Time CAGR -2.9%

Valuation

PE Ratio -29.80

Forward PE N/A

PEG Ratio -1.52

Forward PEG -1.26

PS Ratio N/A

Forward PS 558,590.20

PB Ratio 3.90

P/FCF Ratio -52.08

P/Adj. FCF Ratio -32.37

P/OCF Ratio -48.39

EV/Sales N/A

EV/EBIT -24.52

EV/EBITDA -24.55

EV/FCF -38.75

Earnings Yield -3.4%

FCF Yield -1.9%

Adj. FCF Yield -3.1%

Financial Health

Net Cash $894.24M

Total Debt $1.51M

Cash & Short-Term Investments $895.16M

Total Assets $910.22M

Current Ratio 64.07

Quick Ratio 64.07

Debt / Equity Ratio 0.00

Debt / EBITDA -0.01

Debt / FCF -0.02

OCF / Debt -44.33

Interest Coverage 0.00

Altman Z-Score 140.78

Piotroski F-Score 3

Margins & Profitability

Gross Profit Margin 0.0%

Operating Profit Margin 0.0%

EBITDA Margin 0.0%

Net Profit Margin 0.0%

FCF Margin N/A

Adj. FCF Margin N/A

SBC / Revenue 0.0%

SBC Impact (per share) -60.9%

Returns

Return on Assets -11.6%

Return on Equity -18.6%

Return on Invested Capital -13.9%

Return on Capital Employed -13.9%

Return on Tangible Assets -11.6%

Historical Growth (CAGR)

Revenue CAGR 3Y N/A

Revenue CAGR 5Y N/A

Revenue CAGR 10Y N/A

EPS CAGR 3Y 7.8%

EPS CAGR 5Y 38.5%

EPS CAGR 10Y N/A

FCF CAGR 3Y 3.7%

FCF CAGR 5Y -12.4%

FCF CAGR 10Y N/A

Analyst Forecasts

Analyst Rating Buy

Analyst Count 9

EPS Growth Next 3Y -30.5%

Revenue Growth Next 3Y N/A

Earnings Date Nov 10, 2026

EPS Estimate (next Q) -$0.43

EPS Growth Est (next Q) 34.4%

Revenue Est (next Q) N/A

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $76

Price Target Upside 55.5%

Cash Flow

Operating Cash Flow $-66.94M

Free Cash Flow $-67.04M

Adj. Free Cash Flow $-107.85M

FCF Per Share -$1.01

OCF Per Share -$1.01

OCF/S Ratio 0.0%

Income Statement

Revenue $0

Gross Profit $-60K

Operating Income $-124.41M

EBITDA $-105.81M

Net Income $-105.93M

EPS (Diluted) -$1.64

Revenue / Employee N/A

Profit / Employee $-1.58M

Employees 67